Jessica Mendoza
👤 SpeakerVoice Profile Active
This person's voice can be automatically recognized across podcast episodes using AI voice matching.
Appearances Over Time
Podcast Appearances
The hope was that Cagrosima would be even more effective for weight loss than Eli Lilly's ZepBound.
The hope was that Cagrosima would be even more effective for weight loss than Eli Lilly's ZepBound.
The hope was that Cagrosima would be even more effective for weight loss than Eli Lilly's ZepBound.
But when the data from the clinical trial came out... It just wasn't as good as expected.
But when the data from the clinical trial came out... It just wasn't as good as expected.
But when the data from the clinical trial came out... It just wasn't as good as expected.
It's pretty incredible to think, you know, a few years ago, the idea of a drug being able to reliably help people lose up to 15% of their body weight was unthinkable. And now they're like, oh, only 22%. Sorry. Like, that's mind blowing.
It's pretty incredible to think, you know, a few years ago, the idea of a drug being able to reliably help people lose up to 15% of their body weight was unthinkable. And now they're like, oh, only 22%. Sorry. Like, that's mind blowing.
It's pretty incredible to think, you know, a few years ago, the idea of a drug being able to reliably help people lose up to 15% of their body weight was unthinkable. And now they're like, oh, only 22%. Sorry. Like, that's mind blowing.
Pretty soon, the Novo Nordisk Foundation, the nonprofit running Novo Nordisk the company, started to have concerns over their ability to keep pace with Eli Lilly. And in January, those fears became a reality. New data showed that U.S. prescriptions for Lilly's Zepbound had beaten Novo's Wegovi for the first time.
Pretty soon, the Novo Nordisk Foundation, the nonprofit running Novo Nordisk the company, started to have concerns over their ability to keep pace with Eli Lilly. And in January, those fears became a reality. New data showed that U.S. prescriptions for Lilly's Zepbound had beaten Novo's Wegovi for the first time.
Pretty soon, the Novo Nordisk Foundation, the nonprofit running Novo Nordisk the company, started to have concerns over their ability to keep pace with Eli Lilly. And in January, those fears became a reality. New data showed that U.S. prescriptions for Lilly's Zepbound had beaten Novo's Wegovi for the first time.
And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.
And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.
And so, after eight years of leading Novo and helping it become one of the most profitable drug makers in the world, Jørgensen's time was up. Last Friday, the company announced that the CEO was leaving.
Has Jørgensen himself said anything about the decision?
Has Jørgensen himself said anything about the decision?
Has Jørgensen himself said anything about the decision?
After the announcement, Novo employees gathered to cheer on their departing boss as he descended a winding staircase at the company's headquarters. With Juergensen headed for the exit, the company announced it would bring back someone with deep institutional knowledge, a previous CEO.
After the announcement, Novo employees gathered to cheer on their departing boss as he descended a winding staircase at the company's headquarters. With Juergensen headed for the exit, the company announced it would bring back someone with deep institutional knowledge, a previous CEO.